ArticleThe British journal of ophthalmology2010
Infliximab for the treatment of refractory scleritis.
Article in The British journal of ophthalmology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Guideline
- An Overview of Rheumatoid Arthritis-Associated Dry Eye Disease, Scleritis, and Peripheral Ulcerative Keratitis.Journal of clinical medicine · 2026Review
- Identifying TNF and IL6 as potential hub genes and targeted drugs associated with scleritis: A bio-informative report.Frontiers in immunology · 2023Article
- Immunopathological Analysis of a Mouse Model of Arthritis-Associated Scleritis and Implications for Molecular Targeted Therapy for Severe Scleritis.International journal of molecular sciences · 2021Article
- Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review.Ophthalmology and therapy · 2021Review
- Noninfectious Autoimmune Scleritis: Recognition, Systemic Associations, and Therapy.Current rheumatology reports · 2020Review
- New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy.Mediators of inflammation · 2020Article
- Ocular Manifestations of Granulomatosis with Polyangiitis: A Review of the Literature.Ophthalmology and therapy · 2019Review
- Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation.Journal for immunotherapy of cancer · 2018Article
- Ocular, Auricular, and Oral Manifestations of Inflammatory Bowel Disease.Digestive diseases and sciences · 2017Review
- Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS)-report 4: analysis and outcome of scleritis in an East Asian population.Journal of ophthalmic inflammation and infection · 2017Article
- [Diagnosis and treatment of episcleritis and scleritis].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2016Review
- Biologic therapy for refractory scleritis: a new treatment perspective.International ophthalmology · 2015Review
- Systemic adalimumab induces peripheral corneal infiltrates: a case report.BMC ophthalmology · 2015Article
- Infliximab for peripheral ulcerative keratitis treatment.Medicine · 2014Review
- Ocular inflammatory diseases associated with rheumatoid arthritis.Nature reviews. Rheumatology · 2014Review
- Use of hydroxychloroquine in corticodependent and recurrent scleritis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2013Article
- Pharmacotherapy of scleritis: current paradigms and future directions.Expert opinion on pharmacotherapy · 2013Review
- Combined infliximab and rituximab in necrotising scleritis.Case reports in ophthalmology · 2012Article
- Use of biologic agents in ocular manifestations of rheumatic disease.International journal of rheumatology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Scleritis is a potentially blinding inflammatory disorder. Standard care consists of systemic corticosteroids and immunosuppresants. The authors describe a series of 10 patients suffering from scleritis treated with the TNF inhibitor infliximab because this scleritis was refractory to standard therapy. METHODS The authors reviewed the medical records of patients with scleritis at the Massachusetts Eye Research and Surgery Institution, treated with infliximab. All cases had non-infectious scleritis refractory to traditional immunomodulatory therapy and received 5 mg/kg of infliximab at 4-8-weekly intervals. The main outcome measures evaluated were clinical response, reduction in concomitant immunomodulatory therapy and adverse effects. Inflammation control and visual acuity were assessed using life-table methods. RESULTS A favourable clinical response to infliximab was seen in 100% of the patients, with six (60%) of them achieving remission and cessation of concomitant immunosuppression. A clinical response to infliximab therapy occurred within 13.24 weeks on average. Based on clinical response, the authors found that repeat monthly infusions were required to maintain remission. One (10%) patient developed a lupus-like reaction necessitating discontinuation of infliximab. CONCLUSION Infliximab may be considered in the treatment of non-infectious scleritis refractory to other treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.